Author Correction: Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma

被引：0

作者：

Jennifer N. Brudno

Norris Lam

Danielle Vanasse

Yueh-wei Shen

Jeremy J. Rose

John Rossi

Allen Xue

Adrian Bot

Nathalie Scholler

Lekha Mikkilineni

Mark Roschewski

Robert Dean

Raul Cachau

Philippe Youkharibache

Rashmika Patel

Brenna Hansen

David F. Stroncek

Steven A. Rosenberg

Ronald E. Gress

James N. Kochenderfer

机构：

[1] Experimental Transplantation and Immunotherapy Branch,

[2] Center for Cancer Research,undefined

[3] National Cancer Institute (NCI),undefined

[4] National Institutes of Health (NIH),undefined

[5] Kite Pharma,undefined

[6] Medical Oncology/Hematology Fellowship Program,undefined

[7] NCI,undefined

[8] Lymphoid Malignancy Branch,undefined

[9] Center for Cancer Research,undefined

[10] NCI,undefined

[11] NIH Bethesda,undefined

[12] Cleveland Clinic Taussig Cancer Center,undefined

[13] Advanced Biomedical Computational Science,undefined

[14] Frederick National Laboratory for Cancer Research,undefined

[15] Cancer Data Science Lab,undefined

[16] Center for Cancer Research,undefined

[17] National Cancer Institute,undefined

[18] National Institutes of Health,undefined

[19] Office of Regulatory Affairs,undefined

[20] NCI,undefined

[21] NIH,undefined

[22] Center for Cellular Engineering,undefined

[23] Clinical Center,undefined

[24] NIH,undefined

[25] Surgery Branch,undefined

[26] Center for Cancer Research,undefined

[27] NCI,undefined

[28] NIH Bethesda,undefined

来源：

Nature Medicine | 2020年 / 26卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

引用

页码：803 / 803

共 50 条

[31] HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma
Bourbon, Estelle
Sesques, Pierre
Gossez, Morgane
Tordo, Jeremie
Ferrant, Emmanuelle
Safar, Violaine
Wallet, Florent
Aussedat, Guillaume
Maarek, Alizee
Boua, Fadhela
Karlin, Lionel
Ghergus, Dana
Golfier, Camille
Lequeu, Helene
Lazareth, Anne
Schwiertz, Verane
Viel, Sebastien
Idlhaj, Maryam
Ghesquieres, Herve
Monneret, Guillaume
Bachy, Emmanuel
Venet, Fabienne
BLOOD ADVANCES, 2023, 7 (05) : 744 - 755
[32] Development of a Novel Anti-CD19 CAR Containing a Fully Human scFv and Three Costimulatory Domains
Wutti-In, Yupanun
Sujjitjoon, Jatuporn
Sawasdee, Nunghathai
Panya, Aussara
Kongkla, Katesara
Yuti, Pornpimon
Yongpitakwattana, Petlada
Thepmalee, Chutamas
Junking, Mutita
Chieochansin, Thaweesak
Poungvarin, Naravat
Yamabhai, Montarop
Yenchitsomanus, Pa-thai
FRONTIERS IN ONCOLOGY, 2022, 11
[33] Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma
Chow, Victor A.
Shadman, Mazyar
Gopal, Ajay K.
BLOOD, 2018, 132 (08) : 777 - 781
[34] Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma
Nathalie Scholler
Regis Perbost
Frederick L. Locke
Michael D. Jain
Sarah Turcan
Corinne Danan
Edmund C. Chang
Sattva S. Neelapu
David B. Miklos
Caron A. Jacobson
Lazaros J. Lekakis
Yi Lin
Armin Ghobadi
Jenny J. Kim
Justin Chou
Vicki Plaks
Zixing Wang
Allen Xue
Mike Mattie
John M. Rossi
Adrian Bot
Jérôme Galon
Nature Medicine, 2022, 28 : 1872 - 1882
[35] ENGINEERED T LYMPHOCYTES EXPRESSING AN ANTI-CD19 CAR SPECIFICALLY ERADICATE B-LYMPHOMA CELLS
Tsukahara, Tomonori
Ohmine, Ken
Uchibori, Ryosuke
Urabe, Masashi
Mizukami, Hiroaki
Kume, Akihiro
Riviere, Isabelle
Sadelain, Michel
Brentjens, Renier J.
Ozawa, Keiya
JOURNAL OF GENE MEDICINE, 2014, 16 (7-8): : 249 - 250
[36] Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma
Scholler, Nathalie
Perbost, Regis
Locke, Frederick L.
Jain, Michael D.
Turcan, Sarah
Danan, Corinne
Chang, Edmund C.
Neelapu, Sattva S.
Miklos, David B.
Jacobson, Caron A.
Lekakis, Lazaros J.
Lin, Yi
Ghobadi, Armin
Kim, Jenny J.
Chou, Justin
Plaks, Vicki
Wang, Zixing
Xue, Allen
Mattie, Mike
Rossi, John M.
Bot, Adrian
Galon, Jerome
NATURE MEDICINE, 2022, 28 (09) : 1872 - +
[37] The efficacy of anti-CD19 chimeric antigen receptor T cells for B-cell malignancies
Cao, Jun-Xia
Gao, Wei-Jian
You, Jia
Wu, Li-Hua
Liu, Jin-Long
Wang, Zheng-Xu
CYTOTHERAPY, 2019, 21 (07) : 769 - 781
[38] C-CAR066, a novel fully human anti-CD20 CAR-T therapy for relapsed or refractory large B-cell lymphoma after failure of anti-CD19 CAR-T therapy: A phase I clinical study
Li, Ping
Liu, Wei
Zhou, Lili
Ye, Shiguang
Zhu, Dan
Huang, Jiaqi
Li, Jing
Zheng, Chengxiao
Zhu, Shigui
Yao, Xin
Zhu, Kevin
Yao, Yihong
Qiu, Lugui
Liang, Aibin
Zou, Dehui
AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (12) : 2306 - 2312
[39] INITIAL EXPERIENCE WITH TREATMENT OF HUMAN B-CELL LYMPHOMA WITH ANTI-CD19 MONOCLONAL-ANTIBODY
HEKMAN, A
HONSELAAR, A
VUIST, WMJ
SEIN, JJ
RODENHUIS, S
HUININK, WWT
SOMERS, R
RUMKE, P
MELIEF, CJM
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1991, 32 (06) : 364 - 372
[40] A Feasibility and Safety Study of Non-Viral Genome Targeting Anti-CD19 CAR-T in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Wang, Yi
Wang, Hui
Gao, Ying
Zhang, Ding
Zheng, Yan
Hu, Xingxing
Gao, Qiuying
Peng, Zuohan
Li, Le
Niu, Ben
Hou, Limin
Wang, Ling
Zhang, Weihua
Zhang, Yi
Ru, Xingli
BLOOD, 2020, 136

← 1 2 3 4 5 →